The NC3Rs has an annual budget of around £10 million. We receive core funding from the Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBSRC) and the Home Office.
We also receive funding for specific programmes from the charitable and commercial sectors, and co-funding from other research funders. In 2014/15 this includes the following organisations:
|Association of the British Pharmaceutical Industry1|
|Alzheimer's Research UK|
|Department for Environment, Food and Rural Affairs|
|Engineering and Physical Sciences Research Council|
|Technology Strategy Board|
|The Dow Chemical Company|
1 in accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance, Eli Lily & Co., GlaxoSmithKline, Huntingdon Life Sciences, Novartis, Pfizer, Shire, Takeda and UCB.